Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;41(7):907-922.
doi: 10.1016/j.tibtech.2023.02.003. Epub 2023 Feb 28.

Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy

Dixuan Xue  1 , Shan Lu  1 , Hailing Zhang  1 , Li Zhang  1 , Zhijun Dai  2 , Dan S Kaufman  3 , Jin Zhang  4
Affiliations
Free article
Review

Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy

Dixuan Xue et al. Trends Biotechnol. 2023 Jul.
Free article

Abstract

T cells, natural killer (NK) cells, macrophages (Macs), and dendritic cells (DCs) are among the most common sources for immune-cell-based therapies for cancer. Antitumor activity can be enhanced in induced pluripotent stem cell (iPSC)-derived immune cells by using iPSCs as a platform for stable genetic modifications that impact immuno-activating or -suppressive signaling pathways, such as transducing a chimeric antigen receptor (CAR) or deletion of immunosuppressive checkpoint molecules. This review outlines the utility of four iPSC-derived immune-cell-based therapies, highlight the latest progress and future trends in the genome-editing strategies designed to improve efficacy, safety, and universality, and provides perspectives that compare different contexts in which each of these iPSC-derived immune cell types can be most effectively used.

Keywords: NK cells; T cells; cancer immunotherapy; dendritic cells; gene/cell engineering; genome editing; induced pluripotent stem cells; macrophages.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.Z. is a cofounder of CellOrigin. D.S.K. is a cofounder and advisor to Shoreline Biosciences and has an equity interest in the company. The terms of these arrangements for D.S.K. have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The remaining authors have no interests to declare.